TrialSignal transduction and targeted therapy2024

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial.

Sheng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.